A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
NCT07656415Phase 3Recruiting
- Lead sponsor
- Agios Pharmaceuticals, Inc. (Industry)
- Enrollment
- 159 (estimated)
- Start date
- 21 Jul 2026
- Primary completion
- Aug 2029 (estimated)
- Study completion
- 1 Aug 2030
- Last update posted
- 28 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Mitapivat Matched Placebo Drug
- Mitapivat Drug
Conditions and primary outcome
- Sickle Cell Disease
Primary outcome
Percentage of Subjects who are Transfusion Free From Week 4 Through Week 52 (Week 4 through Week 52)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07656415.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07656415 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.